OCT 7·SEC EDGARLow
Epstein David R purchased $86K of AGMB
Epstein David R purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.64 ($8.57–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$AGMB
AgomAb Therapeutics NV
Price · $AGMBvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $267K 7 txs
- Sells
- — 0 txs
Kemula Pierre Thadee Victor3× · $86K
10b5-1 share of filings0%
Top stories · $AGMBMore →
OCT 7·SEC EDGAR
Kemula Pierre Thadee Victor purchased $86K of AGMB
Kemula Pierre Thadee Victor (Chief Financial Officer) purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.59 ($8.54–$8.67) across 3 trades on 2026-10-06.
OCT 7·SEC EDGAR
Knotnerus Tim Jasper purchased $94K of AGMB
Knotnerus Tim Jasper (Chief Executive Officer) purchased 11,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.58 ($8.48–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.
AGMB sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AGMB (AgomAb Therapeutics NV). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AGMB coverage spans insider activity, financial news and technology.
In the last 30 days, AGMB insiders filed 7 SEC Form 4 transactions — 7 purchases ($267K) and no sales. The most active reporter was Kemula Pierre Thadee Victor, Chief Financial Officer, with 3 filings.
What's driving AGMB
The insider purchase signals confidence from a board member, likely creating slight buying pressure.
The insider purchase signals confidence from management but the transaction size is modest.
Small insider purchase may signal confidence but size is modest.
Positive trial data supports extended dosing and advances the program toward Phase 2b, likely boosting investor sentiment.
The positive trial readout failed to sustain the pre‑market rally, leading to sell pressure.
AlphAI scores every news story that mentions AGMB with an AI model for sentiment and relevance, and aggregates insider trades from AgomAb Therapeutics NV's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AGMB
Score
Epstein David R purchased $86K of AGMB
Epstein David R purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.64 ($8.57–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.
1 min readKemula Pierre Thadee Victor purchased $86K of AGMB
Kemula Pierre Thadee Victor (Chief Financial Officer) purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.59 ($8.54–$8.67) across 3 trades on 2026-10-06.
1 min readKnotnerus Tim Jasper purchased $94K of AGMB
Knotnerus Tim Jasper (Chief Executive Officer) purchased 11,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.58 ($8.48–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.
1 min readH.C. Wainwright reiterates Agomab stock rating on trial data
H.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics (AGMB) after positive Phase 2a STENOVA trial data. The stock is near its 52-week low, down 18% in a week. Analysts' price targets range from $28 to $60. Agomab has no debt and holds more cash, providing financial flexibility. Piper Sandler and B. Riley also initiated coverage with positive ratings and targets of $60 and $34, respectively.
2 min readWhy is Agomab Therapeutics stock sliding today?
Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.
2 min read
Agomab Therapeutics NV (AGMB) Posts Positive 48-Week OLE Data; Plans Phase 2b
Agomab Therapeutics NV (AGMB) reported positive 48-week data for ontunisertib in Crohn’s disease, showing a 3% annualized event rate and favorable safety. The company plans a global Phase 2b study with ~320 patients to start soon.
1 min readThis Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We
BMO Capital initiated coverage on Alnylam Pharmaceuticals (ALNY) with an Outperform rating and $318 price target, BioMarin Pharmaceutical (BMRN) with an Outperform rating and $98 target, and Ionis Pharmaceuticals (IONS) with a Market Perform rating and $60 target. Cantor Fitzgerald initiated Agomab Therapeutics (AGMB) with an Overweight rating. CLSA initiated KE Holdings (BEKE) with an Outperform rating and $23.8 target.
2 min read
AG Mortgage Bank's N3.97bn CP Fully Subscribed
AG Mortgage Bank Plc said its Series 2 and 3 commercial paper issuance under a N5bn programme was fully subscribed, raising N3.97bn. The notes were issued June 10 to June 18 with tenors of 270 and 364 days and gross implied yields of 22.5% to 24%. FSDH Capital led arrangers. For FY2025, interest income rose 28.1% to N3.65bn and profit after tax doubled to N1.05bn.
4 min readAgomab Therapeutics NV (AGMB): Financial results for H2 2026
Agomab Therapeutics NV (AGMB) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook -- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including N
2 min readTop Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus
Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.
7 min read